Wissenschaftliche Arbeiten

Prof. Dr. H. Levent Doğanay

128 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Evaluation of diagnostic performance simple non-invasıve fibrosis markers in patients with chronic hepatitis B

    The Turkish Journal of Gastroenterology, 2019

    DOI 10.5152/tjg.2019.65 Frei zugänglicher VolltextQuelle: OpenAlex

  2. Hepatitis b reactivation rate in patients using anti tnf theraphy: Evaluation of patients not received anti viral prophylaxis

    The Turkish Journal of Gastroenterology, 2019

    DOI 10.5152/tjg.2019.24 Frei zugänglicher VolltextQuelle: OpenAlex

  3. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies

    World Journal of Gastroenterology, 2018

    DOI 10.3748/wjg.v24.i30.3347 PMID 30122875 54 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  4. Identification of a BRCA 2 mutation in a Turkish family with early‐onset breast cancer

    Clinical Case Reports, 2018

    DOI 10.1002/ccr3.1625 PMID 30214756 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  5. P231 CRP/Albumin ratio associated with disease activity in ulcerative colitis

    Journal of Crohn s and Colitis, 2018

    DOI 10.1093/ecco-jcc/jjx180.358 1 Zitation (OpenAlex) Quelle: OpenAlex

  6. Non-alcoholic Fatty Liver Disease: What We Learn from Omics Studies

    InTech eBooks, 2018

    DOI 10.5772/intechopen.71025 Frei zugänglicher VolltextQuelle: OpenAlex

  7. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication

    Arab Journal of Gastroenterology, 2017

    DOI 10.1016/j.ajg.2017.05.002 PMID 28601610 14 Zitationen (Europe PMC) Quelle: OpenAlex

  8. The association of variations in TLR genes and spontaneous immune control of hepatitis B virus

    Clinics and Research in Hepatology and Gastroenterology, 2017

    DOI 10.1016/j.clinre.2017.10.002 PMID 29276096 6 Zitationen (Europe PMC) Quelle: OpenAlex

  9. HLA DPB1 15:01 Allele Predicts Spontaneus Hepatitis B Surface Antigen Seroconversion.

    PubMed, 2017

    PMID 29560661 3 Zitationen (Europe PMC) Quelle: OpenAlex

  10. Hepatocellular Cancer: Is Recurrence Inevitable?

    Journal of Gastrointestinal Cancer, 2017

    DOI 10.1007/s12029-017-9967-0 PMID 28647821 1 Zitation (Europe PMC) Quelle: OpenAlex

  11. Integrating Personalized Genomics To Turkish Health Care System: A Cancer Oriented Pilot Activity of Istanbul Northern Anatolian Public Hospitals with GLAB

    Northern Clinics of Istanbul, 2017

    DOI 10.14744/nci.2017.38980 PMID 28752136 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  12. Can Proteomic Profiling Identify Biomarkers and/or Therapeutic Targets for Liver Fibrosis?

    InTech eBooks, 2017

    DOI 10.5772/65608 Frei zugänglicher VolltextQuelle: OpenAlex

  13. KOLOREKTAL KANSER VE POLİP TARAMASINDA TÜRKİYEVERİLERİ

    Kocaeli Üniversitesi - AVESİS, 2017

    Quelle: OpenAlex

  14. Proteomic profiling of HBV infected liver biopsies with different fibrotic stages

    Proteome Science, 2016

    DOI 10.1186/s12953-017-0114-4 PMID 28439208 23 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  15. Effect of HLA-DPA1 Alleles on Chronic Hepatitis B Prognosis and Treatment Response

    Northern Clinics of Istanbul, 2016

    DOI 10.14744/nci.2016.27870 PMID 28275747 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  16. s There Any Relatıon Between Sıze Of Gastroesophageal Varıces And Chıld Pugh Scores?

    Medeniyet Medical Journal, 2016

    DOI 10.5222/mmj.2016.174 Frei zugänglicher VolltextQuelle: OpenAlex

  17. High treatment modification rates with lamivudine therapy in HBV ‐infected patients with low baseline viremia and early virological response: A multicenter study

    Journal of Digestive Diseases, 2015

    DOI 10.1111/1751-2980.12237 PMID 25708813 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  18. HLA DQB1 alleles are related with nonalcoholic fatty liver disease

    Molecular Biology Reports, 2014

    DOI 10.1007/s11033-014-3688-2 PMID 25156535 11 Zitationen (Europe PMC) Quelle: OpenAlex

  19. Association of human leukocyte antigen DQB1 and DRB1 alleles with chronic hepatitis B

    World Journal of Gastroenterology, 2014

    DOI 10.3748/wjg.v20.i25.8179 PMID 25009391 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  20. Efficacy of Two Levofloxacin‐Containing Second‐Line Therapies for H elicobacter pylori: A Pilot Study

    Helicobacter, 2013

    DOI 10.1111/hel.12056 PMID 23601026 13 Zitationen (Europe PMC) Quelle: OpenAlex

  21. Last Blood Check Before Passing: Does Alcohol Prevent Fibrosis?

    The American Journal of Gastroenterology, 2013

    DOI 10.1038/ajg.2013.74 PMID 23735920 Quelle: OpenAlex

  22. Assessment of endothelial function in patients with nonalcoholic fatty liver disease

    Endocrine, 2012

    DOI 10.1007/s12020-012-9712-1 PMID 22661277 61 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  23. Relation of epicardial adipose tissue and carotid intima-media thickness in patients with nonalcoholic fatty liver disease

    European Journal of Gastroenterology & Hepatology, 2012

    DOI 10.1097/meg.0b013e3283513f19 PMID 22495402 39 Zitationen (Europe PMC) Quelle: OpenAlex

  24. Nonalcoholic Fatty Liver Disease: A Nutritional Approach

    Metabolic Syndrome and Related Disorders, 2012

    DOI 10.1089/met.2011.0145 PMID 22394108 19 Zitationen (Europe PMC) Quelle: OpenAlex

  25. Concentrations of Connective Tissue Growth Factor in Patients with Nonalcoholic Fatty Liver Disease: Association with Liver Fibrosis

    Disease Markers, 2012

    DOI 10.1155/2012/283726 PMID 22846210 14 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  26. Serum osteopontin levels as a predictor of portal inflammation in patients with nonalcoholic fatty liver disease

    Digestive and Liver Disease, 2012

    DOI 10.1016/j.dld.2012.08.017 PMID 22995553 23 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  27. The effect of HLA-DQB1 alleles on virologic breakthroughs during chronic hepatitis B treatment with genetically low barrier drugs

    Clinics and Research in Hepatology and Gastroenterology, 2012

    DOI 10.1016/j.clinre.2012.10.013 PMID 23273495 5 Zitationen (Europe PMC) Quelle: OpenAlex

  28. İnflamatuar Barsak Hastalıklarında Ekstraintestinal Bulgular

    Turkiye Klinikleri Gastroenterohepatology - Special Topics, 2012

    Quelle: OpenAlex

  29. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease

    Medical Science Monitor, 2011

    DOI 10.12659/msm.881749 PMID 21525818 120 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  30. Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease

    Metabolic Syndrome and Related Disorders, 2011

    DOI 10.1089/met.2011.0111 PMID 22112193 20 Zitationen (Europe PMC) Quelle: OpenAlex

  31. Is the Lymphoma Risk Reduced in Viral Hepatitis? A Cirrhotic Patient With Triple Malignancies

    The American Journal of Gastroenterology, 2011

    DOI 10.1038/ajg.2011.214 PMID 21897412 Quelle: OpenAlex

  32. Response (with video)

    Gastrointestinal Endoscopy, 2010

    DOI 10.1016/j.gie.2010.06.034 Quelle: OpenAlex

  33. Instant control of fundal variceal bleeding with a folkloric medicinal plant extract: Ankaferd Blood Stopper

    Gastrointestinal Endoscopy, 2009

    DOI 10.1016/j.gie.2009.08.021 PMID 19922917 30 Zitationen (Europe PMC) Quelle: OpenAlex

  34. Mesalazine-induced myopericarditis in a patient with ulcerative colitis

    International Journal of Colorectal Disease, 2005

    DOI 10.1007/s00384-004-0706-1 PMID 15726390 16 Zitationen (Europe PMC) Quelle: OpenAlex

  35. Yilmaz Y, Zeybel M, Adali G, et al. (including Doganay L). TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease. Hepatology Forum. 2023;4(Suppl 1):1–32. https://doi.org/10.14744/hf.2023.2023.0011

    Quelle: Profilseite auf livhospital.com

  36. Bulur A, Özdil K, Bilgiç NM, Kürbüz K, Öztürk O, Çalışkan Z, Sayar S, Atalay R, Doğanay HL. Bilateral subcapsular cataract in a patient with Crohn's disease taking oral budesonide therapy: A case report. Journal of European Internal Medicine Professionals. 2023;1(4):167–169. https://doi.org/10.5281/zenodo.10019776

    Quelle: Profilseite auf livhospital.com

  37. Temiz MZ, Hacibey I, Yazar RO, Sevdi MS, Kucuk SH, Alkurt G, Doganay L, Dinler Doganay G, Dincer MM, Yuruk E, Erkalp K, Muslumanoglu AY. Altered kidney function induced by SARS-CoV-2 infection and acute kidney damage markers predict survival outcomes of COVID-19 patients: A prospective pilot study. Renal Failure. 2022;44(1):233–240. https://doi.org/10.1080/0886022X.2022.2032743

    Quelle: Profilseite auf livhospital.com

  38. Tanriover MD., Doğanay L, Akova M., Güner HR, Azap A, Akhan S., Köse Ş,Erdinç FŞ, Akalın EH., Tabak EF, Pullukçu H., Batum Ö., Yavuz S., Turhan Ö., Yıldırmak MT., Köksal İ., Taşova Y., Korten V., Yılmaz G., Çelen MK., Altın S., Çelik İ., Bayındır Y., Karaoğlan İ., Yılmaz A., Özkul A., Gür H., Unal S., and the CoronaVac Study Group. Efficacy and safety of an inactivated whole virion SARS-CoV-2 vaccine, CoronaVac: interim results of a randomised, double-blind, placebo-controlled phase III clinical trial in Turkey, Lancet 2021;398(10296):213-22. doi: 10.1016/S0140-6736(21)01429-X.

    Quelle: Profilseite auf livhospital.com

  39. Tanriover MD., Doğanay L, Serhat Ünal, Akova M. Coronavac efficacy data from Turkey. Lancet 2021; 398(10314):1874. doi: 10.1016/S0140-6736(21)02286-8.

    Quelle: Profilseite auf livhospital.com

  40. Altay O., Yang H., Aydin M., Alkurt G., Altunal N., Kim W., Akyol D., Arif M., Zhang C., Dinler-Doganay G., Turkez H., Shoaie S., Nielsen J., Boren J., Doganay L., Uhlen M., Mardinoglu A. Combined metabolic coactivators accelerates recovery in mild to-moderate COVID-19, Advanced Science. doi.org/10.1002/advs.202101222

    Quelle: Profilseite auf livhospital.com

  41. Can N. D., Basturk E., Kizilboga T., Akcay I. M., Dingiloglu B., Acar S., Elibeyli E., Muratcıoglu S., Januzzi A., Gursoy A., Keskin O., Doganay H. L., Karademir-Yilmaz B., Dinler-Doganay G. Interactome analysis of Bag-1 isoforms reveals novel interaction partners in ER- associated degradation. Plos One 2021;16(8):e0256640. doi: 10.1371/journal.pone.0256640

    Quelle: Profilseite auf livhospital.com

  42. Sayar S., Gökçen P., Aykut H., Adalı G., Doğanay HL, Özdil K. Can simple Non-Invasive Fibrosis Models Determine Prognostic Indicators (Fibrosis and Treatment Response) of Primary Biliary Cholangitis? Med Bull Sisli Etfal Hosp 2021;55(3):412–418. doi: 10.14744/SEMB.2021.95825

    Quelle: Profilseite auf livhospital.com

  43. Bulur A, Ozdil K, Doganay L, Ozturk O, Kahraman R, Demirdag H, Caliskan Z, Mutlu Bilgic N, Kanat E, Serap Erden A, Mehmet Sokmen H. Polypoid lesions detected in the upper gastrointestinal endoscopy: A retrospective analysis in 19560 patients, a single-center study of a 5-year experience in Turkey. North Clin Istanb. 2020 Nov 27;8(2):178-185. doi: 10.14744/nci.2020.16779.

    Quelle: Profilseite auf livhospital.com

  44. Geyik G, Sahin A, Pekcioglu Y, Okuroglu N, Doganay L, Ozdil K. Is NRS-2002 a reliable tool in the nutritional assessment of cirrhosis: A comparative study. Acta Medica Mediterranea. 2021;37(1):43–50.

    Quelle: Profilseite auf livhospital.com

  45. Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Ozdil K., Doganay L. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. Journal of Viral Hepatitis. 2021;28(5).

    Quelle: Profilseite auf livhospital.com

  46. Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, Melidou A, Neher RA, O'Toole Á, Pereyaslov D; WHO European Region sequencing laboratories and GISAID EpiCoV group\. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Euro Surveill. 2020 Aug;25(32):2001410. doi: 10.2807/1560-7917.ES.2020.25.32.2001410.

    Quelle: Profilseite auf livhospital.com

  47. Karacan I, Akgun TK, Agaoglu NB, Irvem A, Alkurt G, Yildiz J, Kose B, Ozel AS, Altunal LN, Can ND, Demirkol YK, Aydin M, Dogan OA, Doganay L, Doganay GD. The origin of SARS-CoV-2 in Istanbul: Sequencing findings from the epicenter of the pandemic in Turkey. North Clin Istanb. 2020;7(3):203-209. doi: 10.14744/nci.2020.90532.

    Quelle: Profilseite auf livhospital.com

  48. Temiz MZ, Dincer MM, Hacibey I, Yazar RO, Celik C, Kucuk SH, Alkurt G, Doganay L, Yuruk E, Muslumanoglu AY. Investigation of SARS-CoV-2 in semen samples and the effects of COVID-19 on male sexual health by using semen analysis and serum male hormone profile: A cross-sectional, pilot study. Andrologia. 2020(26): e13912. doi: 10.1111/and.13912.

    Quelle: Profilseite auf livhospital.com

  49. Demir F, Bolac GL, Merter T, Canbek S, Dogan OA, Demirkol YK, Yildiz J, Doganay HL, Sozeri B. The musculoskeletal system manifestations in children with familial Mediterranean fever. North Clin Istanb. 2020 4;7(5):438-442. doi: 10.14744/nci.2020.96636.

    Quelle: Profilseite auf livhospital.com

  50. Sayar S, Kurbuz K, Kahraman R, Caliskan Z, Atalay R, Ozturk O, Doganay HL, Ozdil K. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. North Clin Istanb. 2019:25;7(1):49-55. doi: 10.14744/nci.2018.78800.

    Quelle: Profilseite auf livhospital.com